ARTICLE | Financial News
Accent targeting RNA-modifying proteins with $40M series A
May 18, 2018 9:12 AM UTC
RNA epigenetics company Accent Therapeutics Inc. (Lexington, Mass.) debuted with a $40 million series A co-led by The Column Group and Atlas Venture, with participation from EcoR1 Capital...
BCIQ Company Profiles